AJAC  Vol.3 No.7 , July 2012
Development and Validation of Stability Indicating LC Method for 10-Hydroxycamptothecin
Abstract: The present method gives a detailed description for the development and validation of a simple stability indicating reverse phase liquid chromatographic method for 10-hydroxycamptothecin(10-HCTN) in the presence of its impurities namely Imp A and Imp B along with degradation products generated from forced degradation studies. The drug was subjected to stress conditions of hydrolysis (acid, base and neutral), oxidative, photolytic and thermal stress degradation. Degradation was observed when subjected to treatment with peroxides or under conditions normally used for typical acid and base hydrolysis. The drug was found to be stable under other stress conditions attempted such as photolytic and thermal. Successful separation and isolation of the drug from related impurities and degradation products formed under stress conditions was achieved on an Inertsil ODS-3V (250 mm × 4.6 mm, 5 μm) column using a phosphate buffer, acetonitrile, methanol and Nanopure water. The developed HPLC method was validated with respect to specificity, linearity, accuracy, precision, sensitivity, robustness and solution stability. The assay method was found to be linear in the range of 0.16 mg/mL to 0.24 mg/mL with a correlation coefficient of 0.999 and the linearity of the impurities was established from 0.02% (LOQ) to 0.3%. Recoveries of assay and impurities were found between 99.4% and 100.3%. The developed HPLC method can be used to determine the related substances and assay determinations of 10-HCTN and also to evaluate the quality and long term stability of production samples.
Cite this paper: A. Venkateshwarlu, A. Rao and K. Mukkanti, "Development and Validation of Stability Indicating LC Method for 10-Hydroxycamptothecin," American Journal of Analytical Chemistry, Vol. 3 No. 7, 2012, pp. 470-477. doi: 10.4236/ajac.2012.37062.

[1]   Y. H. Ping, H. C. Lee, J. Y. Lee, P. H. Wu, L. K. Ho, C. W. Chi, M. F. Lu and J. J. Wang, “Anticancer Effects of Low-Dose 10-Hydroxycamptothecin in Human Colon Cancer,” Oncology Reports, Vol. 15, No. 5, 2006, pp. 1273- 1279.

[2]   R. P. Hertzberg, M. J. Caranfa and S. M. Hecht, “On the Mechanism of Topoisomerase I Inhibition by Camptothecin: Evidence for Binding to an Enzyme-DNA Complex,” Nucleic Acids Research, Vol. 21, No. 3, 1993, pp. 593- 600.

[3]   Y. H. Ling, R. Perez-Soler and M. T. Tseng, “Effect of DNA Topoisomerase I Inhibitor, 10-Hydroxycamptothecin, on the Structure and Function of Nuclei and Nuclear Matrix in Bladder Carcinoma MBT-2 Cells,” Anticancer Research, Vol. 13, No. 5A, 1993, pp. 1613-1617.

[4]   P. I. Yan, K. Jiang, R. Hou, Y. Gong, J. Lin, X. Sun and K. Tang, “Examination of Camptothecin and 10-Hydroxy-camptothecin in Camptothecaacuminata Plant and Cell Culture, and the Affected Yields Under Several Cell Culture Treatments,” Biocell Official Journal of the Sociedades Latinoamericanas de Microscopia Electronica et al., Vol. 34, No. 3, 2010, pp. 139-143.

[5]   ICH Steering Committee, “Impurities in New Drug Substances,” International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use, Chicago, 25 October 2006.

[6]   M. E. Wall, M. C. Wani, A. W. Nicholas, G. Mani Kumar and C. Tele, “Plant Antitumor Agents. 30. Synthesis and Structure Activity of Novel Camptothecin Analogs,” Journal of Medicinal Chemistry, 1993, Vol. 36, No. 18, pp. 2689-2700. doi:10.1021/jm00070a013

[7]   R. Rao and A. V. Rama Rao, “Method of Synthesizing the Key Intermediates for the Production of Camptothecin Derivatives,” US 0221358 A1, 2008.

[8]   J. Ma, Z. P. Jia, Q. Zhang, J. J. Fan, N. Jiang, R. Wang, H. Xie and J. Wang, “Liquid Chromatography Determination of 10-Hydroxycamptothecin in Human Serum by a Column-Switching System Containing a Precolumn with Re-stricted Access Media and its Application to a Clinical Pharmacokinetic Study,” Journal of Chromatography, Vol. 796, No. 1, 2003, pp. 195-200.

[9]   IFPMA, “Stability Testing of New Drug Substances and Drug Products Q1A(R2),” International Conference on Harmonization, Geneva, 2003.

[10]   ICH Steer-ing Committee, “Validation of Analytical Procedures,” International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use, 27 October 1994.